View of Cost-effectiveness analysis of prophylaxis with emicizumab or bypassing agents in children with severe haemophilia A and high-response inhibitors after immunotolerance failure in Brazil

Return to Article Details Cost-effectiveness analysis of prophylaxis with emicizumab or bypassing agents in children with severe haemophilia A and high-response inhibitors after immunotolerance failure in Brazil Download Download PDF